Exploring 3 High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has risen by 5.7%, contributing to a remarkable increase of 37% over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AsiaFIN Holdings	51.75%	58.17%	★★★★★★
Invivyd	47.87%	67.72%	★★★★★★
Sarepta Therapeutics	23.89%	42.65%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.45%	70.66%	★★★★★★
Blueprint Medicines	25.26%	68.92%	★★★★★★
Travere Therapeutics	31.20%	72.26%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

CleanSpark (NasdaqCM:CLSK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CleanSpark, Inc. operates as a bitcoin miner in the Americas with a market cap of $3.50 billion.

Operations: The company generates revenue primarily through its Bitcoin Mining Business, which reported $342.21 million. The focus on bitcoin mining highlights a concentrated revenue stream within the digital currency sector.

CleanSpark, showcasing resilience and adaptability, recently resumed operations post-Hurricane Helene with a hashrate rebound to 28.7 EH/s, underscoring its robust recovery mechanisms. Amidst operational updates, the company also expanded its financial flexibility by doubling authorized shares to 600 million, reflecting potential for future growth initiatives or equity-based financing. Financially, CleanSpark is poised for significant growth with revenue expected to surge at an annual rate of 37.2%, outpacing the broader US market's 8.9%. Moreover, earnings are projected to skyrocket by approximately 83.4% annually over the next three years, indicating strong future profitability despite current unprofitability and recent shareholder dilution.

• Dive into the specifics of CleanSpark here with our thorough health report.

• Gain insights into CleanSpark's past trends and performance with our Past report.

TG Therapeutics (NasdaqCM:TGTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases globally, with a market cap of $4.13 billion.

Operations: TG Therapeutics focuses on developing and commercializing treatments for B-cell mediated diseases, generating revenue primarily from its biotechnology startup segment, which amounts to $264.79 million.

TG Therapeutics has demonstrated a notable resilience in its financial and operational performance, with revenue growth forecasted at 34.7% annually, significantly outpacing the US market average of 8.9%. This robust expansion is underpinned by promising clinical outcomes from their ULTIMATE I & II Phase 3 trials for BRIUMVI in multiple sclerosis, showing a marked reduction in annualized relapse rates and stable immunoglobulin levels over five years. Despite recent setbacks reflected in Q3 earnings—where net income sharply fell to $3.88 million from $113.93 million year-over-year—the company's strategic inclusion in indices such as the S&P 1000 underscores its potential within the biotech sector. With R&D efforts yielding continuous treatment benefits and safety profiles, TG Therapeutics is poised to leverage its scientific advancements for future growth, especially as it transitions towards profitability with an expected profit surge of 56.5% annually over the next three years.

• Delve into the full analysis health report here for a deeper understanding of TG Therapeutics.

• Gain insights into TG Therapeutics' historical performance by reviewing our past performance report.

Ubiquiti (NYSE:UI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ubiquiti Inc. develops networking technology for service providers, enterprises, and consumers with a market capitalization of approximately $18.92 billion.

Operations: The company generates revenue primarily from its Wireless Communications Equipment segment, which accounted for approximately $2.02 billion.

Ubiquiti's recent financial performance underscores its resilience in the tech sector, with a notable increase in quarterly sales from $463.08 million to $550.34 million and a jump in net income from $87.75 million to $127.99 million, reflecting a robust growth trajectory. This upward trend is mirrored by an anticipated annual earnings growth of 29% over the next three years, outpacing the US market forecast of 15.5%. Despite being dropped from the FTSE All-World Index, Ubiquiti maintains strong shareholder returns with consistent dividend affirmations, highlighting its commitment to delivering value amidst dynamic market conditions. The company's strategic focus on innovation is evident from its R&D investments aimed at driving further growth within the competitive tech landscape.

• Click here and access our complete health analysis report to understand the dynamics of Ubiquiti.

• Review our historical performance report to gain insights into Ubiquiti's's past performance.

Seize The Opportunity

• Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 240 more companies for you to explore.Click here to unveil our expertly curated list of 243 US High Growth Tech and AI Stocks.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com